Advertisement
UK markets open in 2 hours 49 minutes

  • NIKKEI 225

    38,399.00
    +846.84 (+2.26%)
     

  • HANG SENG

    17,097.12
    +268.19 (+1.59%)
     

  • CRUDE OIL

    83.43
    +0.07 (+0.08%)
     

  • GOLD FUTURES

    2,341.50
    -0.60 (-0.03%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,483.65
    +67.73 (+0.13%)
     

  • CMC Crypto 200

    1,435.11
    +20.35 (+1.44%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

Reuters - UK Focus

LONDON, Dec (Shanghai: 600875.SS - news) 5 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare (Shanghai: 603313.SS - news) , to be replaced by GSK insider Deborah Waterhouse.

Waterhouse, currently in charge of primary care within GSK's U.S. pharmaceuticals operation, will take over as ViiV chief executive at the same time as Emma Walmsley takes the helm of the wider GSK group.

Limet has led ViiV for the past seven years. In recent times sales have grown strongly on the back of new HIV medicines. Pfizer (NYSE: PFE - news) and Shionogi are minority shareholders in ViiV. (Reporting by Ben Hirschler; Editing by Ruth Pitchford)